

Figure S1 Distribution of recurrence score result in meta-analysis population. RS, 12-gene Oncotype DX Colon Recurrence Score result.




Figure S2 Meta-analysis tests of interaction among common covariates. Ratio of HR (estimates and 95% CI) with meta-analysis Wald test P values. Studies with no recurrence event in an interaction category excluded. RS, 12-gene Oncotype DX Colon Recurrence Score result; MMR, mis-match repair; HR, hazard ratios; CI, confidence intervals.




Figure S3 Meta-analysis tests of interaction of common covariates with stage III vs. II. Ratio of HR (estimates and 95% CI) with meta-analysis Wald test P values. RS, 12-gene Oncotype DX Colon Recurrence Score result; MMR, mis-match repair; HR, hazard ratios; CI, confidence intervals.




Figure S4 Tests of interaction of treatment with other covariates in NSABP C-07. Ratio of HR: estimates and 95% CI with Wald test P values. There were insufficient recurrence events among MMR-deficient patients to test for interaction. RS, 12-gene Oncotype DX Colon Recurrence Score result; HR, hazard ratios; 5FU, fluorouracil; CI, confidence intervals; MMR, mis-match repair.




Figure S5 Meta-analysis estimates and 95% CI for HR of high tumor grade and right-sided tumor location with recurrence: univariable analysis and multivariable together with stage, RS, number of nodes examined, T-stage, and MMR status; meta-analysis Wald test P values. CI, confidence intervals; HR, hazard ratios; RS, 12-gene Oncotype DX Colon Recurrence Score result; MMR, mis-match repair.

Table S1 Correlations among model factors

Factor	<12 nodes examined	T-stage 4	MMR deficient	Stage IIIAB vs. II	Stage IIIC vs. II
RS	-0.02	0.13	0.03	0.02	0.03
<12 nodes examined		0.03	-0.12	0.03	-0.03
T-stage T4			0.08	0.00	0.01
MMR deficient				-0.02	-0.01

MMR, mis-match repair.

Table S2 Exploratory analysis assessing the incremental prognostic value of right-sidedness tumor location

Effect	CALGB 9581 (n=690)*, 162 events	SUNRISE (n=597)*, 202 events	NSABP C-07 (n=892), 245 events
RS per 25 units	1.57 (1.14, 2.18); P=0.006	1.99 (1.37, 2.88); P<0.001	1.78 (1.36, 2.32); P<0.001
<12 vs. ≥12 nodes examined	1.12 (0.79, 1.59); P=0.53	1.78 (1.23, 2.58); P=0.002	1.50 (1.16, 1.95); P=0.002
T-stage T4 vs. T3	1.04 (0.51, 2.13); P=0.92	1.18 (0.80, 1.73); P=0.41	2.70 (1.80, 4.04); P<0.001
MMR deficient vs. proficient/unknown	0.62 (0.39, 1.01); P=0.056	0.76 (0.32, 1.79); P=0.53	0.28 (0.12, 0.63); P=0.002
Stage IIIAB vs. II	-	2.31 (1.64, 3.25); P<0.001	2.32 (1.57, 3.52); P<0.001
Stage IIIC vs. II	-	5.29 (3.39, 8.27); P<0.001	5.64 (3.75, 8.47); P<0.001
Oxali + 5FU vs. 5FU	-	-	0.80 (0.62, 1.03); P=0.084
Right-sided tumor	0.99 (0.70, 1.14); P=0.97	0.84 (0.60, 1.17); P=0.30	1.12 (0.86, 1.45); P=0.40

Cox proportional hazards regression model HR with 95% CI and Wald test P values. RS, 12-gene Oncotype DX Colon Cancer Recurrence Score result; MMR, mis-match repair; Oxali, oxaliplatin; HR, hazard ratios; CI, confidence intervals.

Table S3 Exploratory analysis assessing the incremental prognostic value of tumor grade

Effect	CALGB 9581 (n=690)*, 162 events	SUNRISE (n=597)*, 202 events	NSABP C-07 (n=892), 245 events
RS per 25 units	1.56 (1.14, 2.15); P=0.006	1.97 (1.36, 2.84); P<0.001	1.67 (1.27, 2.19); P<0.001
<12 vs. ≥12 nodes examined	1.09 (0.80, 1.50); P=0.59	1.85 (1.29, 2.65); P=0.001	1.49 (1.15, 1.92); P<0.003
T-stage T4 vs. T3	1.07 (0.56, 2.03); P=0.85	1.19 (0.81, 1.75); P=0.38	2.72 (1.81, 4.07); P<0.001
MMR deficient vs. proficient/ unknown	0.71 (0.44, 1.16); P=0.17	0.73 (0.31, 1.72); P=0.47	0.27 (0.12, 0.61); P=0.002
Stage IIIAB vs. II	–	2.30 (1.63, 3.24); P<0.001	2.26 (1.52, 3.38); P<0.001
Stage IIIC vs. II	–	5.32 (3.42, 8.26); P<0.001	5.47 (3.65, 8.20); P<0.001
Oxali + 5FU vs. 5FU	–	–	0.82 (0.64, 1.06); P=0.14
High tumor grade	0.80 (0.54, 1.18); P=0.26	0.89 (0.53, 1.49); P=0.64	1.36 (1.09, 1.81); P=0.037

Cox proportional hazards regression model HR with 95% CI and Wald test P values. RS, 12-gene Oncotype DX Colon Cancer Recurrence Score result; MMR, mis-match repair; Oxali, oxaliplatin; HR, hazard ratios; CI, confidence intervals.